527 completed, 141 terminated, 117 recruiting, 94 unknown. 1045 Phase 1, 378 Phase 2.
Follow Breast Cancer: new trials by email Literature Review of Breast Cancer trials Research Report on Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Multi-4SCAR-T Therapy Targeting Breast Cancer 4SCAR T cells - Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-06-01 | 2026-08-26 |
| Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases Trastuzumab Deruxtecan, Stereotactic Radiosurgery - Breast Cancer, HER2-positive Breast Cancer | Phase 1 | Not yet recruiting | Baptist Health South Florida | 20 | 2027-01-01 | 2026-10-01 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080 HRS-8080, Rifampicin - Breast Cancer | Phase 1 | Not yet recruiting | Shandong Suncadia Medicine Co., Ltd. | 18 | 2026-11-01 | 2026-10-15 |
| Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity 68Ga-Galmydar, PET/MRI, 18F-FDG - Lymphoma Cancer, Breast Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 36 | 2026-11-01 | 2026-09-24 |
| A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer PRT13722, Fulvestrant, Abemaciclib - Breast Cancer, Hormone-receptor-positive Breast Cancer | Phase 1 | Not yet recruiting | Prelude Therapeutics Incorporated | 242 | 2026-10-30 | 2026-10-29 |
| A Study of 68Ga-FAPI Breast PET/MRI Scans in People With Breast Cancer 68Ga-FAPI-PET/MRI - Breast Cancer, Invasive Breast Cancer | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 10 | 2026-10-20 | 2026-10-28 |
| Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic STRO-006, Pembrolizumab - Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer | Phase 1 | Recruiting | Sutro Biopharma, Inc. | 285 | 2026-10-19 | 2026-10-23 |
| Comparative Study of QL1209 and Perjeta® in Healthy Male Participants QL1209, US-Perjeta® - Breast Cancer | Phase 1 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 80 | 2026-10-01 | 2026-10-09 |
| Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells, Trastuzumab deruxtecan (T-DXd), Rimiducid - Breast Cancer | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 60 | 2026-10-01 | 2026-08-19 |
| CBD for Breast Cancer Primary Tumors CBD Oral, Control - Breast Cancer | Phase 1 | Recruiting | Medical University of South Carolina | 84 | 2026-09-18 | 2026-09-28 |
| Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer Neoadjuvant Chemotherapy, Radiation Therapy, MRI - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 84 | 2026-09-15 | 2026-06-24 |
| Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects TQB3126 - Breast Cancer | Phase 1 / Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 300 | 2026-09-12 | 2026-10-20 |
| HER2 Vaccine for Locally Advanced Breast Cancer HER2 Vaccine - Breast Cancer, HER2-positive Breast Cancer | Phase 1 | Recruiting | Pravin T.P Kaumaya | 36 | 2026-09-01 | 2026-08-27 |
| BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder Aromatase Inhibitors, Bupropion, GnRH agonist - Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Illinois at Chicago | 100 | 2026-09-01 | 2026-08-24 |
| Study of SKB103 in HER2-negative Breast Cancer SKB103 monotherapy - Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 140 | 2026-08-31 | 2026-08-19 |
| A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors SI-B036 - Breast Cancer, Solid Tumor | Phase 1 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 39 | 2026-08-18 | 2026-09-10 |
| SL-28 for Advanced Solid Tumours SL-28 - Head & Neck Cancer, Pancreas Carcinoma | Phase 1 / Phase 2 | Recruiting | Second Life Therapeutics | 60 | 2026-08-14 | 2026-09-15 |
| TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer HTR2 T Cells - Breast Cancer, Tumor, Breast | Phase 1 | Recruiting | Baylor College of Medicine | 27 | 2026-08-03 | 2026-09-24 |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
Showing 20 of 1045. Sign in to see all of them.
Breast Neoplasms (1045) · Ovarian Neoplasms (178) · Colorectal Neoplasms (116) · Lung Neoplasms (114) · Carcinoma, Non-Small-Cell Lung (112) · Pancreatic Neoplasms (105) · Prostatic Neoplasms (104) · Neoplasm Metastasis (81) · Stomach Neoplasms (81) · Neoplasms (80) · Melanoma (74) · Colonic Neoplasms (62) · Head and Neck Neoplasms (61) · Triple Negative Breast Neoplasms (54) · Endometrial Neoplasms (50)
Skin and Connective Tissue Diseases (1045) · Skin Diseases (1043) · Neoplasms by Site (1041) · Breast Diseases (1038) · Neoplasms (965) · Urogenital Diseases (258) · Urogenital Neoplasms (252) · Genital Diseases (240) · Neoplasms by Histologic Type (238) · Endocrine System Diseases (234) · Endocrine Gland Neoplasms (233) · Female Urogenital Diseases (228) · Female Urogenital Diseases and Pregnancy Complications (228) · Digestive System Diseases (220) · Digestive System Neoplasms (219)
Paclitaxel (73) · Trastuzumab (71) · Cyclophosphamide (63) · Fulvestrant (41) · Docetaxel (40) · pembrolizumab (40) · Capecitabine (32) · Carboplatin (32) · Doxorubicin (28) · Letrozole (27) · palbociclib (26) · Filgrastim (23) · Gemcitabine (21) · Lapatinib (20) · abemaciclib (20)
National Cancer Institute (NCI) (33) · Memorial Sloan Kettering Cancer Center (30) · M.D. Anderson Cancer Center (23) · Dana-Farber Cancer Institute (15) · Novartis Pharmaceuticals (15) · Pfizer (15) · Abramson Cancer Center at Penn Medicine (12) · Hoffmann-La Roche (12) · AstraZeneca (11) · Eli Lilly and Company (11) · Genentech, Inc. (11) · National University Hospital, Singapore (10) · Sichuan Baili Pharmaceutical Co., Ltd. (10) · H. Lee Moffitt Cancer Center and Research Institute (9) · Masonic Cancer Center, University of Minnesota (9)
United States (690) · China (130) · Spain (73) · Canada (62) · France (62) · United Kingdom (54) · Australia (52) · Belgium (35) · Italy (35) · South Korea (35) · Netherlands (27) · Japan (26) · Germany (21) · Singapore (19) · Taiwan (15)
Soo Chin Lee (4) · Beth A. Overmoyer, MD, FACP (3) · Brian Czerniecki, M.D., Ph.D. (3) · David Avigan, MD (3) · Filipa Lynce, MD (3) · Herbert K. Lyerly, MD (3)
PMID 12473512, PMID 16157940, PMID 16546506, PMID 16758122, PMID 16783576, PMID 17273752, PMID 17906897, PMID 18245541, PMID 18392824, PMID 18536917, PMID 18726994, PMID 19351776, PMID 20113933, PMID 20845479, PMID 21332269, PMID 21730275, PMID 21989902, PMID 25144817, PMID 30627694, PMID 32385714, PMID 32819975, PMID 35482127, PMID 38753757, PMID 40443562, PMID 10026920, PMID 10602908, PMID 11359672, PMID 11410496, PMID 11807794, PMID 12114401, PMID 12218176, PMID 12788172, PMID 14767498, PMID 15018740, PMID 15539915, PMID 15550580, PMID 15588380, PMID 16198508, PMID 16478735, PMID 17344671, PMID 17426973, PMID 17472472, PMID 18035213, PMID 18245546, PMID 18294778, PMID 18327587, PMID 18424887, PMID 18446090, PMID 18474099, PMID 18483372
2023 (11), 2015 (10), 2014 (8), 2017 (6), P30CA033572 (6), 2018 (5), 2016 (4), 2019 (4), 2025 (4), P30CA006973 (4), P30CA072720 (4), 2008 (3), 2009 (3), P30CA022453 (3), P30CA043703 (3)